Molecular profiling (World Health Organization [WHO] grades II–III) has classified lower-grade gliomas (LLGs) into three distinct molecular subgroups: isocitrate dehydrogenase (IDH) wildtype, IDH-mutated with 1p/19q codeletion, and IDH-mutated without 1p/19q codeletion [3]. This evidence concerns the gene IDH1 and central nervous system cancer.